Literature DB >> 24848366

The effectiveness of prefrontal theta cordance and early reduction of depressive symptoms in the prediction of antidepressant treatment outcome in patients with resistant depression: analysis of naturalistic data.

Martin Bares1, Tomas Novak, Miloslav Kopecek, Martin Brunovsky, Pavla Stopkova, Cyril Höschl.   

Abstract

Current studies suggest that an early improvement of depressive symptoms and the reduction of prefrontal theta cordance value predict the subsequent response to antidepressants. The aim of our study was (1) to compare the predictive abilities of early clinical improvement defined as ≥ 20 % reduction in Montgomery and Åsberg Depression Rating Scale (MADRS) total score at week 1 and 2, and the decrease of prefrontal theta cordance at week 1 in resistant depressive patients and (2) to assess whether the combination of individual predictors yields more robust predictive power than either predictor alone. Eighty-seven subjects were treated (≥ 4 weeks) with various antidepressants chosen according to the judgment of attending psychiatrists. Areas under curve (AUC) were calculated to compare predictive effect of defined single predictors (≥ 20 % reduction in MADRS total score at week 1 and 2, and the decrease of cordance at week 1) and combined prediction models. AUCs of all three predictors were not statistically different (pair-wise comparison). The model combining all predictors yielded an AUC value 0.91 that was significantly higher than AUCs of each individual predictor. The results indicate that the combined predictor model may be a useful and clinically meaningful tool for the prediction of antidepressant response in patients with resistant depression.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24848366     DOI: 10.1007/s00406-014-0506-8

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  50 in total

1.  IFCN guidelines for topographic and frequency analysis of EEGs and EPs.The International Federation of Clinical Neurophysiology.

Authors:  M R Nuwer; D Lehmann; F L da Silva; S Matsuoka; W Sutherling; J F Vibert
Journal:  Electroencephalogr Clin Neurophysiol Suppl       Date:  1999

Review 2.  Frontocingulate dysfunction in depression: toward biomarkers of treatment response.

Authors:  Diego A Pizzagalli
Journal:  Neuropsychopharmacology       Date:  2010-09-22       Impact factor: 7.853

3.  Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.

Authors:  Madhukar H Trivedi; A John Rush; Stephen R Wisniewski; Andrew A Nierenberg; Diane Warden; Louise Ritz; Grayson Norquist; Robert H Howland; Barry Lebowitz; Patrick J McGrath; Kathy Shores-Wilson; Melanie M Biggs; G K Balasubramani; Maurizio Fava
Journal:  Am J Psychiatry       Date:  2006-01       Impact factor: 18.112

4.  Electroencephalographic alpha measures predict therapeutic response to a selective serotonin reuptake inhibitor antidepressant: pre- and post-treatment findings.

Authors:  Gerard E Bruder; James P Sedoruk; Jonathan W Stewart; Patrick J McGrath; Frederic M Quitkin; Craig E Tenke
Journal:  Biol Psychiatry       Date:  2007-12-03       Impact factor: 13.382

5.  Changes in brain function during administration of venlafaxine or placebo to normal subjects.

Authors:  Andrew F Leuchter; Ian A Cook; David J DeBrota; Aimee M Hunter; William Z Potter; Caroline C McGrouther; Melinda L Morgan; Michelle Abrams; Barbara Siegman
Journal:  Clin EEG Neurosci       Date:  2008-10       Impact factor: 1.843

6.  Early reduction in prefrontal theta QEEG cordance value predicts response to venlafaxine treatment in patients with resistant depressive disorder.

Authors:  Martin Bares; Martin Brunovsky; Miloslav Kopecek; Tomas Novak; Pavla Stopkova; Jiri Kozeny; Peter Sos; Vladimir Krajca; Cyril Höschl
Journal:  Eur Psychiatry       Date:  2008-05-02       Impact factor: 5.361

7.  Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder.

Authors:  Andrew F Leuchter; Ian A Cook; William S Gilmer; Lauren B Marangell; Karl S Burgoyne; Robert H Howland; Madhukar H Trivedi; Sidney Zisook; Rakesh Jain; Maurizio Fava; Dan Iosifescu; Scott Greenwald
Journal:  Psychiatry Res       Date:  2009-08-26       Impact factor: 3.222

Review 8.  The subgenual anterior cingulate cortex in mood disorders.

Authors:  Wayne C Drevets; Jonathan Savitz; Michael Trimble
Journal:  CNS Spectr       Date:  2008-08       Impact factor: 3.790

9.  Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy.

Authors:  Raymond W Lam; Sidney H Kennedy; Sophie Grigoriadis; Roger S McIntyre; Roumen Milev; Rajamannar Ramasubbu; Sagar V Parikh; Scott B Patten; Arun V Ravindran
Journal:  J Affect Disord       Date:  2009-08-11       Impact factor: 4.839

10.  Is it worth assessing progress as early as week 2 to adapt antidepressive treatment strategy? Results from a study on agomelatine and a global meta-analysis.

Authors:  P Gorwood; F Bayle; G Vaiva; P Courtet; E Corruble; P-M Llorca
Journal:  Eur Psychiatry       Date:  2013-02-14       Impact factor: 5.361

View more
  15 in total

1.  Pathways to personalized treatment strategies for depressive disorders.

Authors:  Dorota M Badowska; Daniela Reich-Erkelenz; Andrea Schmitt; Peter Falkai
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-02       Impact factor: 5.270

Review 2.  Progress in Elucidating Biomarkers of Antidepressant Pharmacological Treatment Response: A Systematic Review and Meta-analysis of the Last 15 Years.

Authors:  G Voegeli; M L Cléry-Melin; N Ramoz; P Gorwood
Journal:  Drugs       Date:  2017-12       Impact factor: 9.546

Review 3.  Rhythms and blues: modulation of oscillatory synchrony and the mechanism of action of antidepressant treatments.

Authors:  Andrew F Leuchter; Aimee M Hunter; David E Krantz; Ian A Cook
Journal:  Ann N Y Acad Sci       Date:  2015-03-23       Impact factor: 5.691

4.  Electroencephalographic Biomarkers for Treatment Response Prediction in Major Depressive Illness: A Meta-Analysis.

Authors:  Alik S Widge; M Taha Bilge; Rebecca Montana; Weilynn Chang; Carolyn I Rodriguez; Thilo Deckersbach; Linda L Carpenter; Ned H Kalin; Charles B Nemeroff
Journal:  Am J Psychiatry       Date:  2018-10-03       Impact factor: 18.112

5.  Pilot Study of An Intracranial Electroencephalography Biomarker of Depressive Symptoms in Epilepsy.

Authors:  Katherine W Scangos; Hasan S Ahmad; Alia Shafi; Kristin K Sellers; Heather E Dawes; Andrew Krystal; Edward F Chang
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2019-08-09       Impact factor: 2.198

Review 6.  Intermediate phenotypes and biomarkers of treatment outcome in major depressive disorder.

Authors:  Andrew F Leuchter; Aimee M Hunter; David E Krantz; Ian A Cook
Journal:  Dialogues Clin Neurosci       Date:  2014-12       Impact factor: 5.986

Review 7.  Prediction of response to drug therapy in psychiatric disorders.

Authors:  Shani Stern; Sara Linker; Krishna C Vadodaria; Maria C Marchetto; Fred H Gage
Journal:  Open Biol       Date:  2018-05       Impact factor: 6.411

8.  Special Report on the Impact of the COVID-19 Pandemic on Clinical EEG and Research and Consensus Recommendations for the Safe Use of EEG.

Authors:  Salvatore Campanella; Kemal Arikan; Claudio Babiloni; Michela Balconi; Maurizio Bertollo; Viviana Betti; Luigi Bianchi; Martin Brunovsky; Carla Buttinelli; Silvia Comani; Giorgio Di Lorenzo; Daniel Dumalin; Carles Escera; Andreas Fallgatter; Derek Fisher; Giulia Maria Giordano; Bahar Guntekin; Claudio Imperatori; Ryouhei Ishii; Hendrik Kajosch; Michael Kiang; Eduardo López-Caneda; Pascal Missonnier; Armida Mucci; Sebastian Olbrich; Georges Otte; Andrea Perrottelli; Alessandra Pizzuti; Diego Pinal; Dean Salisbury; Yingying Tang; Paolo Tisei; Jijun Wang; Istvan Winkler; Jiajin Yuan; Oliver Pogarell
Journal:  Clin EEG Neurosci       Date:  2020-09-25       Impact factor: 1.843

Review 9.  QEEG in affective disorder: about to be a biomarker, endophenotype and predictor of treatment response.

Authors:  Sermin Kesebir; Ahmet Yosmaoğlu
Journal:  Heliyon       Date:  2018-08-22

10.  BDNF Plasma Levels and BDNF Exon IV Promoter Methylation as Predictors for Antidepressant Treatment Response.

Authors:  Klaus Lieb; Nadine Dreimüller; Stefanie Wagner; Konrad Schlicht; Tanja Falter; Alexandra Neyazi; Linda Müller-Engling; Stefan Bleich; André Tadić; Helge Frieling
Journal:  Front Psychiatry       Date:  2018-10-26       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.